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Risk-benefit analysis of tuberculosis infection testing for 
household contact management in high-burden countries: 
a mathematical modelling study
Courtney M Yuen, James A Seddon, Salmaan Keshavjee, Peter J Dodd
Summary
Background Preventive therapy for tuberculosis reduces the risk of disease in people who have been infected but who 
are not sick. Countries with a high burden of tuberculosis that are expanding preventive therapy use must decide how 
tuberculosis infection testing should be used for risk stratiication among household contacts of patients with 
tuberculosis.
Methods We modelled the risks of tuberculosis disease and severe adverse events, comparing the following 
two preventive therapy strategies: preventive therapy for all household contacts, or preventive therapy for only 
household contacts with a positive tuberculin skin test (TST) result. We used data from clinical trials and literature on 
tuberculosis natural history to model outcomes, assuming diferent preventive therapy regimens, ages, and TST 
positivity prevalence.
Findings Assuming 25% prevalence of TST positivity among 1000 household contacts aged 0–17 years, a treat-all 
approach with isoniazid and rifapentine compared with a treat-TST-only approach led to 13 fewer incident tuberculosis 
cases (IQR –5 to –18) and four additional severe adverse events (2 to 6). With rifampicin, the diference was 11 fewer 
incident tuberculosis cases (–3 to –17) and two additional severe adverse events (1 to 3). For adults, a treat-all approach 
led to fewer incident tuberculosis cases, and additional adverse events increased with age. Assuming 25% prevalence 
of TST positivity among adult contacts, a treat-all approach would lead to around two fewer tuberculosis cases per 
1000 contacts for all regimens; the number of additional severe adverse events ranged from seven (IQR 5 to 8) for 
18 to 34-year-olds treated with rifampicin to 63 (50 to 74) for people older than 64 years treated with isoniazid 
and rifapentine. A rifampicin-only regimen was associated with the fewest additional severe adverse events (seven 
[IQR 5 to 8] per 1000 adults aged 18–34 years and 35–64 years, and 17 [9 to 23] per 1000 adults older than 64 years).
Interpretation Based on the available data, giving preventive therapy to all household contacts would probably reduce 
the incidence of tuberculosis cases in high-burden settings. Adverse events could be minimised by using non-
isoniazid regimens and, in adults older than 18 years, focusing treatment on individuals with a positive infection test.
Funding Bill & Melinda Gates Foundation, UK Medical Research Council, and UK Department for International 
Development.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
An estimated 10 million people develop tuberculosis 
globally every year, including 1 million children.1 When a 
person is infected with the bacterium that causes 
tuberculosis, disease might develop rapidly or after a 
period of time, with the highest risk of disease occurring in 
the irst 1–2 years.2 If a person is infected but has not yet 
developed disease, the infection can be treated with 
preventive therapy. Clinical trials have established the 
efectiveness of preventive therapy to be 60–70% in 
reducing the risk of developing tuberculosis disease.3 
Mathematical modelling suggests that along with active 
case-inding and efective treatment, preventing the 
development of tuberculosis disease is a critical component 
of a comprehensive global tuberculosis strategy, without 
which tuberculosis elimination cannot be achieved.4,5
Close contacts of patients with tuberculosis, particularly 
those in the same household, are a priority group for 
preventive therapy given the high probability of recent 
infection. In low-income and middle-income countries, 
around 45% of household contacts have been found to 
have latent tuberculosis infection on average.6 Best practice 
for managing household contacts of a newly diagnosed 
tuberculosis patient involves prompt evalu ation of all 
household members, treatment of those with tuberculosis 
disease, and provision of preventive therapy to those who 
do not have tuberculosis disease but who are at risk of 
developing disease in the future.7 Guidelines for risk 
stratiication to decide who should get preventive therapy 
vary across countries.8 In settings with low tuberculosis 
incidence, preventive therapy is generally ofered to 
contacts who test positive for tuberculosis infection, 
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as well as others at particularly high risk of disease 
progression. In many settings with high tuberculosis 
incidence, guidelines recommend preven tive therapy for 
only contacts younger than 5 years and people living with 
HIV—the perceived highest-risk groups—without testing 
for tuberculosis infection. However, it is estimated that 
globally, if all household contacts younger than 15 years 
were evaluated and given preventive therapy if infected but 
not sick, 160 000 tuberculosis cases among children could 
be averted annually.9 Reductions in morbidity would be 
even greater if adult household contacts with tuberculosis 
infection were also treated.5
Given the importance of tuberculosis infection treatment 
in combating the global tuberculosis epidemic, WHO 
released updated guidance in 2018 supporting expanded 
use of preventive therapy in countries with high 
tuberculosis burdens.7 As many of these countries consider 
revising national guidelines to expand use of preventive 
therapy beyond young children and people living with 
HIV, the question arises of whether tuberculosis infection 
testing should be used for risk stratiication among 
contacts, as is done in low-burden settings. Available tests 
for tuberculosis infection include skin tests (most 
commonly the tuberculin skin test [TST]) and interferon 
gamma release assay (IGRA) blood tests. Both types of test 
detect an immune response to Mycobacterium tuberculosis 
antigens but cannot distinguish between current infection 
and an infection cleared by the immune system. Both can 
give false negative results in people with compromised 
immune systems or very recent infection, and the two tests 
can give discordant results.10 Given their imperfect 
sensitivity,10 the negative predictive value of the tests for 
detecting tuberculosis infection is restricted where 
prevalence of tuberculosis infection is high. Moreover, 
both types of test have only partial value in predicting 
future tuberculosis disease.11 Finally, logistical barriers 
have limited the use of these tests in resource-poor 
settings—the TST requires cold-chain storage and two 
visits to complete, the IGRA requires a blood sample and 
laboratory infrastructure, and both require trained health 
staf to implement.
Given both diagnostic limitations and logistical 
challenges associated with tuberculosis infection testing 
in high-burden settings, an alternative approach would 
be to give preventive therapy to all household contacts 
once disease has been ruled out, as is done for young 
children and people living with HIV. However, preventive 
therapy can cause adverse events; therefore, it is 
necessary to weigh the risk that a person will develop 
tuberculosis against the risk of adverse events and ensure 
that the risk–beneit assessment is favourable. Multiple 
factors afect this risk–beneit assessment. Both the risk 
of developing tuberculosis disease and the risk of adverse 
events associated with preventive therapy vary by age.2,12 
Research in context
Evidence before this study
Systematic reviews have quantified the effectiveness of 
preventive therapy for reducing the risk of tuberculosis disease. 
Mathematical modelling studies have projected that 
elimination of tuberculosis globally will require increased use of 
preventive therapy. A systematic review quantified the risks of 
adverse events associated with different preventive therapy 
regimens, and several studies have reported that adverse event 
risk—particularly for hepatotoxicity—increases with age. 
To determine whether these data had been combined in a 
mathematical model to compare the risks and benefits of 
preventive therapy, we did a PubMed search on Oct 24, 2019, 
with no language restrictions, for studies published since 
inception, combining the tuberculosis infection terms (“latent 
tuberculosis” OR “tuberculosis infection” OR “TB infection” OR 
“preventive therapy”) with variants of the term “mathematical 
modelling”. This search yielded 98 articles, of which 25 reported 
modelling of preventive therapy interventions. Only one of 
these included adverse events as an outcome, comparing 
incident tuberculosis cases and hepatitis events that would be 
expected if people over 60 years old in Hong Kong were tested 
for latent tuberculosis infection and treated with isoniazid.
Added value of this study
To our knowledge, this study is the first to model both incident 
tuberculosis cases and adverse events associated with different 
preventive therapy strategies for contact management in high-
burden settings. We separately modelled these outcomes for 
different age groups and different preventive therapy regimens, 
and we compared strategies of treating all contacts and 
treating only contacts with positive tuberculin skin tests. 
We incorporate in our model systematic review evidence on the 
efficacy of different preventive therapy regimens and 
age-stratified adverse event risk data from recent trials of 
rifapentine-based and rifampicin-based regimens.
Implications of all the available evidence
In settings with high tuberculosis burdens, expanding use of 
preventive therapy to all contacts will help to accelerate 
declines in tuberculosis incidence. For contacts younger than 
18 years, tuberculosis infection testing might not be 
necessary, as treating all contacts in this age group with 
preventive therapy would lead to substantially more 
protection with minimal additional adverse events compared 
with giving preventive therapy to only those with confirmed 
infection. When expanding preventive therapy to older 
contacts, adverse events are more of a concern; however, 
these can be minimised by using a rifampicin-only regimen, 
focusing treatment on those with a positive infection test, 
and actively monitoring patients at higher risk of adverse 
events via regular evaluation of signs and symptoms and liver 
function testing.
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Moreover, risks of adverse events are diferent for the four 
currently recommended preventive therapy regimens for 
drug-susceptible tuberculosis infection.7
There is a lack of clear guidance available to enable high-
burden settings to develop contact management policies 
that expand the use of preventive therapy beyond young 
children and people living with HIV. To help ill this 
knowledge gap, we did a modelling exercise comparing 
the risk of future tuberculosis disease progression and the 
risk of severe adverse events associated with the following 
two preventive therapy strategies: giving preventive 
therapy to all household contacts of patients with 
tuberculosis or giving preventive therapy to only TST-
positive household contacts.
Methods
Model framework
To robustly explore uncertainty around individual-level 
beneits and harms and to avoid assumptions about 
transmission epidemiology, we used a decision tree 
model framework (igure 1). Risk of tuberculosis disease 
progression was dependent on TST status and receipt of 
preventive therapy, and anyone who received preventive 
therapy had a risk of severe adverse events. We did 
separate analyses for diferent age groups since the risk 
of disease progression and severe adverse events vary by 
age.2,12 We did separate analyses for diferent preventive 
therapy regimens for which appropriate data were 
available, including 3 months of weekly isoniazid and 
rifapentine, 4 months of daily rifampicin, and 6 months 
of daily isoniazid. Appropriate data were unavailable for 
the 3 months of daily isoniazid and rifampicin regimen, 
the 1 month of daily isoniazid and rifapentine regimen, 
or regimens for drug-resistant tuberculosis. Modelling 
and analyses were done using R version 3.6. All code and 
data are available at the GitHub repository.
Interventions and outcomes
For each age group and regimen, we compared two 
strategies: one in which all household contacts received 
preventive therapy (treat all), and one in which all 
household contacts were tested for tuberculosis infection 
by TST, but only those with a positive TST result received 
preventive therapy (treat TST-positive only). We assessed 
the following two outcomes of interest: incident tubercu-
losis disease and severe adverse events. Tuberculosis 
disease was considered a inal endpoint, after which 
we did not consider whether treatment of tuberculosis 
Figure 1: Model decision tree for tuberculosis disease and severe adverse event outcomes
TST=tuberculin skin test.
Tuberculosis disease 
Adverse event 
No adverse event 
Adverse event 
No adverse event 
No preventive therapy
Preventive therapy
Household contact of 
patient with tuberculosis
TST-negative
TST-positive
No preventive therapy
Preventive therapy
No tuberculosis disease 
Tuberculosis disease 
No tuberculosis disease 
Tuberculosis disease 
No tuberculosis disease 
Tuberculosis disease 
No tuberculosis disease 
Tuberculosis disease 
No tuberculosis disease 
Tuberculosis disease 
No tuberculosis disease 
For the GitHub repository see 
https://github.com/petedodd/
prerib
Articles
e675 www.thelancet.com/lancetgh   Vol 8   May 2020
disease might incur adverse events or cause additional 
disease or infection via transmission. Severe adverse 
events were conceptualised as the equivalent of grade 3 or 
higher adverse events based on standardised grading 
criteria used in clinical trials. Grade 3 adverse events are 
not life-threatening but are severe enough to be disabling 
or to warrant hospitalisation; grade 4 adverse events are 
life-threatening.13
Model parameters
Table 1 summarises the parameters used in the model. 
We sought to obtain age-stratiied estimates of the risk of 
tuberculosis progression in household contacts in the 
absence of preventive therapy. We used data from a 
previous study that described the risk of disease after 
infection among TST-positive household contacts in 
Australia using an imputation model to remove the efect 
of the tuberculosis infection treatment.2 We estimated 
risk of progression within 3 years by using the cumulative 
risk starting 3 months after index patient diagnosis 
(appendix p 1), assuming that secondary cases developing 
before that point would be diagnosed during the initial 
contact evaluation process and could not beneit from 
preventive therapy. For the 0–17 years age group in the 
model, we used a weighted average of the progression 
probabilities and variances for ages 0–4 years (weight 1) 
and 5–14 years (weight 2). For progression risk in TST-
negative household contacts, we used UK data on 
tuberculosis incidence stratiied by TST status (10 mm 
cutof)14 to parameterise a risk ratio for progression. 
Because this cohort study used TST results to deine the 
comparison groups, the model parameter derived from 
this study takes into account the limited sensitivity 
(estimated to be around 72%) and speciicity (estimated 
to be around 98% in a non-BCG-vaccinated population 
and 56% in a BCG-vaccinated population) of the TST.10
For the efect of diferent preventive therapy regimens 
in reducing tuberculosis disease risk, we used the eicacy 
estimates from a meta-analysis of randomised controlled 
trials.3 We assumed 100% uptake of preventive therapy 
if prescribed. We did not assume 100% treatment 
completion, as the eicacy estimates we used relect the 
actual treatment completion rates observed in the studies 
contributing to the meta-analysis. We assumed eicacy 
to be consistent across age groups. We assumed that the 
reduction in relative risk of tuberculosis is the same 
for TST-positive and TST-negative contacts, although 
the absolute risk reduction is diferent because the 
underlying risk of tuberculosis in untreated contacts is 
diferent. We conservatively assumed that a person who 
had a severe adverse event would derive no beneit from 
preventive therapy.
To obtain age-stratiied data on serious adverse events 
for adults (age ≥18 years), we contacted authors of the 
3 months of weekly isoniazid and rifapentine and 
4 months of daily rifampicin eicacy trials.16,18 The most 
common adverse event associated with 9 months of daily 
isoniazid and 4 months of daily rifampicin was drug-
induced hepatitis,18 whereas the most common adverse 
event associated with 3 months of weekly isoniazid and 
rifapentine was hypersensitivity.16 For the 3 months of 
weekly isoniazid and rifapentine trial, we obtained the 
number and proportion of patients with grade 3–4 
adverse events attributed to treatment in the isoniazid-
rifapentine group. From the 4 months of daily rifampicin 
trial, we obtained the number and proportion of patients 
with grade 3–4 adverse events attributed to treatment and 
leading to treatment discontinuation from the 4 months 
of daily rifampicin and 9 months of daily isoniazid study 
groups. We obtained similar data for children (0–17 years) 
from published paediatric trials.15,17 We assumed that 
adverse event data for 9 months of daily isoniazid apply 
to the 6 months of daily isoniazid regimen; we thought 
this reasonable because in the 3 months of weekly 
isoniazid and rifapentine eicacy trial, around 90% of 
the adverse-event-associated discontinuations in the 
9 months of daily isoniazid group occurred within 
6 months.19
Age group (years) Estimate (IQR)
Probability of progression to tuberculosis disease if TST-positive but not sick, 3 months to 3 years after 
infection
Trauer et al, 20162 0–17 0·132 (0·087–0·188)
Trauer et al, 20162 18–34 0·022 (0·016–0·030)
Trauer et al, 20162 35–64 0·022 (0·016–0·030)
Trauer et al, 20162 ≥65 0·022 (0·016–0·030)
Risk ratio for progression to tuberculosis disease in contacts who are TST-negative versus TST-positive
Abubakar et al, 201814 All 0·155 (0·132–0·183)
3 months of weekly isoniazid and rifapentine efficacy among people with positive TST, as OR
Zenner et al, 20173 All 0·226 (0·167–0·306)
4 months of daily rifampicin efficacy among people with positive TST, as OR
Zenner et al, 20173 All 0·335 (0·260–0·432)
6 months of daily isoniazid efficacy among people with positive TST, as OR
Zenner et al, 20173 All 0·391 (0·338–0·452)
Probability of severe adverse event while receiving 3 months of weekly isoniazid and rifapentine
Villarino et al, 201515 0–17 0·005 (0·003–0·007)
Unpublished data from authors of Sterling et al16 18–34 0·020 (0·018–0·023)
Unpublished data from authors of Sterling et al16 35–64 0·042 (0·039–0·045)
Unpublished data from authors of Sterling et al16 ≥65 0·082 (0·067–0·099)
Probability of severe adverse event while receiving 4 months of daily rifampicin
Diallo et al, 201817 0–17 0·002 (0·001–0·004)
Unpublished data from authors of Menzies et al18 18–34 0·008 (0·007–0·010)
Unpublished data from authors of Menzies et al18 35–64 0·009 (0·007–0·011)
Unpublished data from authors of Menzies et al18 ≥65 0·020 (0·012–0·031)
Probability of severe adverse event while receiving 6 months of daily isoniazid
Diallo et al, 201817 0–17 0·002 (0·001–0·003)
Unpublished data from authors of Menzies et al18 18–34 0·015 (0·013–0·018)
Unpublished data from authors of Menzies et al18 35–64 0·028 (0·025–0·031)
Unpublished data from authors of Menzies et al18 ≥65 0·053 (0·040–0·068)
TST=tuberculin skin test. OR=odds ratio.
Table 1: Model parameters
See Online for appendix
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Uncertainty in parameters was modelled with 
appropriate distributions with parameters that were 
matched to evidence by moment matching (appendix 
pp 2–4). We report IQRs around mean outcomes, 
calculated as the 25th and 75th percentiles in model 
outputs across 10 000 sampled input parameter sets.
Model outputs
We irst modelled the risk of incident tuberculosis 
disease within 3 years and the risk of a severe adverse 
event for four age groups (0–17 years, 18–34 years, 
35–64 years, and ≥65 years), stratiied by TST status, 
under four treatment conditions (no treatment, 3 months 
of weekly isoniazid and rifapentine, 4 months of daily 
rifampicin, and 6 months of daily isoniazid). We then 
used these outputs to model the risk diference between 
the two treatment strategies (treat all vs treat TST-positive 
contacts only), by age group, and for populations with 
diferent prevalence of TST positivity. Finally, as an 
illustrative example, we modelled the overall risk 
diference for hypothetical populations of household 
contacts with age structure and TST positivity similar to 
what has been reported from a high-burden setting (New 
Delhi)20 and from a low-burden setting (Amsterdam).21 
These population parameters are shown in the 
appendix (p 5). The purpose of this model was not to 
make treatment recommendations for high-burden and 
low-burden settings, but rather to illustrate how the same 
treatment strategy can lead to diferent consequences 
when applied to populations with diferent age structures 
and TST prevalence.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had inal 
responsibility for the decision to submit for publication.
Results
We estimated the risk of incident tuberculosis disease in 
3 years and risk of severe adverse events, by age group, 
TST status, and preventive therapy regimen, among 
household contacts who did not have tuberculosis disease 
upon initial evaluation (igure 2). For each 1000 children 
aged 0–17 years with a positive TST, the number expected 
to develop tuberculosis in 3 years with no treatment would 
be 145 (IQR 87–190), compared with 42 (20–54) with 
3 months of weekly isoniazid and rifapentine, 59 (29–77) 
with 4 months of daily rifampicin, and 65 (35–86) with 
6 months of daily isoniazid. By contrast, for each 1000 
adults aged 18–34 years, the number expected to develop 
tuberculosis in 3 years with no treatment would be 
24 (16–30) compared with seven (3–8) with 3 months 
Figure 2: Predicted 3-year risk of tuberculosis disease and risk of severe adverse events among household contacts who do not have tuberculosis disease at 
initial evaluation, by age group, tuberculin skin test status, and preventive therapy regimen
Error bars represent IQRs.
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of weekly isoniazid and rifapentine, nine (5–11) with 
4 months of daily rifampicin, and ten (6–13) with 6 months 
of daily isoniazid. The tuberculosis risks for other adult 
age groups were similar to these results.
Table 2 shows the risks of incident tuberculosis disease 
and severe adverse events expected in diferent age 
groups when using diferent regimens, assuming a 25% 
prevalence of TST positivity for each age group and 
comparing a treat-all approach with an approach of 
treating only TST-positive contacts. For children aged 
0–17 years, the number of severe adverse events predicted 
was lower than the number of tuberculosis cases that 
would arise without treatment, regardless of treatment 
approach and regimen. For adults, this remained true 
only for the treat-TST-only approach, and only for certain 
age group and regimen combinations. Results assuming 
diferent prevalence of TST positivity are shown in the 
appendix (pp 6–8).
Figure 3 shows the diferences in the risk of incident 
tuberculosis and the risk of severe adverse events 
associated with a treat-all strategy compared with a 
strategy of treating TST-positive contacts. When using 
3 months of weekly isoniazid and rifapentine to treat 
1000 child contacts aged 0–17 years, 25% of whom had a 
positive TST, the treat-all approach led to a diference 
of –13 (IQR –5 to –18) in the number of tuberculosis 
cases and a diference of four (2 to 6) in the number of 
severe adverse events compared with treating only those 
with a positive TST. Results were similar for other 
regimens (appendix p 9). The treat-all approach led to an 
increasing number of additional severe adverse events as 
age increased, with 4 months of daily rifampicin 
producing the smallest increase. When using 3 months 
of weekly isoniazid and rifapentine to treat 1000 adult 
contacts aged 65 years and older, 25% of whom had a 
positive TST, the treat-all approach led to a diference 
of –2 (–1 to –3) tuberculosis cases and a diference of 
63 (50 to 74) severe adverse events compared with treating 
only those with a positive TST. By contrast, when using 
4 months of daily rifampicin, the treat-all approach led 
to a diference of –2 (–1 to –3) tuberculosis cases and a 
diference of 17 (9 to 23) in severe adverse events. As 
the prevalence of TST positivity increased, the number 
of TST-negative contacts excluded from the treat-TST-
positive strategy decreased; therefore, the diferences in 
outcomes between the two strategies diminished.
Table 3 shows the results of applying these risk 
diferences to hypothetical populations of contacts in 
high-burden and low-burden settings. In the high-
burden setting, a treat-all strategy across all age groups 
using 3 months of weekly isoniazid and rifapentine led 
to a diference of –4 (IQR –6 to –2) tuberculosis cases and 
a diference of nine (8 to 10) severe adverse events per 
1000 contacts compared with the strategy of treating only 
TST-positive contacts. In the low-burden setting, the 
treat-all strategy with 3 months of weekly isoniazid and 
rifapentine led to a diference of –3 (–4 to –2) tuberculosis 
cases and a diference of 38 (34 to 42) in severe adverse 
events per 1000 contacts.
Discussion
Treating tuberculosis infection with preventive therapy is 
a critical component of a comprehensive strategy 
to eliminate the disease.22 When comparing treat-all 
and treat-TST-positive-only approaches to preventive 
therapy, we found that outcomes varied on the basis of 
age, preventive therapy regimen, and prevalence of TST 
positivity. Among child contacts younger than 18 years, a 
treat-all approach could avert more cases of tubercu losis 
disease and would incur a minimal increase in severe 
adverse events, regardless of preventive therapy regimen 
and prevalence of TST positivity. For adults, isoniazid-
containing regimens were generally associ ated with 
more adverse events than rifampicin alone. Moreover, for 
adults, our model suggests that, since the risk of adverse 
events increases with age, risk stratiication using TST 
could reduce the risk of treatment-related adverse events, 
and increased monitoring for adverse events such as 
hepatoxicity is warranted in older age groups receiving 
preventive therapy. In weighing up the risks and beneits 
of widening the delivery of preventive therapy, our results 
Treat all Treat TST-positive only
Tuberculosis 
cases per 
1000 contacts
Severe adverse 
events per 
1000 contacts
Tuberculosis 
cases per 
1000 contacts
Severe adverse 
events per 
1000 contacts
0–17 years
No preventive therapy 53·3 (37·3–66·5) 0·0 (0·0–0·0) 53·3 (37·3–66·5) 0·0 (0·0–0·0)
3 months of weekly isoniazid 
and rifapentine
14·9 (8·8–18·8) 5·6 (2·9–7·4) 27·7 (18·2–34·9) 1·4 (0·7–1·9)
4 months of daily rifampicin 21·0 (12·9–26·7) 3·0 (0·9–4·2) 31·9 (21·3–39·7) 0·7 (0·2–1·0)
6 months of daily isoniazid 23·3 (15·2–29·2) 2·5 (0·7–3·5) 33·4 (22·8–41·6) 0·6 (0·2–0·9)
18–34 years
No preventive therapy 8·9 (6·5–10·8) 0·0 (0·0–0·0) 8·9 (6·5–10·8) 0·0 (0·0–0·0)
3 months of weekly isoniazid 
and rifapentine
2·4 (1·5–3·0) 20·3 (17·6–22·6) 4·5 (3·2–5·5) 5·1 (4·4–5·7)
4 months of daily rifampicin 3·3 (2·2–4·0) 8·8 (7·0–10·3) 5·1 (3·6–6·2) 2·2 (1·7–2·6)
6 months of daily isoniazid 3·7 (2·6–4·5) 15·4 (13·1–17·5) 5·4 (3·9–6·5) 3·9 (3·3–4·4)
35–64 years
No preventive therapy 8·8 (6·6–10·7) 0·0 (0·0–0·0) 8·9 (6·5–10·8) 0·0 (0·0–0·0)
3 months of weekly isoniazid 
and rifapentine
2·5 (1·6–3·1) 41·8 (38·6–44·9) 4·6 (3·2–5·6) 10·5 (9·7–11·2)
4 months of daily rifampicin 3·3 (2·2–4·1) 9·0 (7·3–10·5) 5·1 (3·6–6·3) 2·3 (1·8–2·6)
6 months of daily isoniazid 3·7 (2·7–4·6) 28·1 (25·2–30·8) 5·4 (4·0–6·5) 7·0 (6·3–7·7)
≥65 years
No preventive therapy 8·8 (6·5–10·7) 0·0 (0·0–0·0) 8·8 (6·5–10·7) 0·0 (0·0–0·0)
3 months of weekly isoniazid 
and rifapentine
2·8 (1·9–3·4) 84·0 (67·1–98·7) 4·8 (3·4–5·8) 21·0 (16·7–24·7)
4 months of daily rifampicin 3·3 (2·2–4·1) 23·1 (12·0–30·9) 5·1 (3·6–6·3) 5·8 (3·0–7·7)
6 months of daily isoniazid 3·9 (2·7–4·7) 55·1 (40·0–67·6) 5·5 (4·0–6·7) 13·8 (10·0–16·9)
Data are mean (IQR). TST=tuberculin skin test.
Table 2: Risks of incident tuberculosis and severe adverse events incurred by treating all contacts or 
treating only TST-positive contacts, assuming 25% prevalence of TST positivity, by age and regimen
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must be considered in light of the fact that, should an 
adult develop tuberculosis disease, the risk of adverse 
events during treatment and poor outcomes from 
treatment also increases with age.23 Finally, applying the 
same risk stratiication approach in high-burden and 
low-burden settings can have diferent implications in 
terms of disease and adverse event outcomes, therefore 
optimal approaches that balance risks and beneits will 
probably difer across settings.
Our indings could help guide policy decisions around 
when to make tuberculosis infection tests a prerequisite 
for preventive therapy among household contacts. In 
high-burden settings that are already treating contacts 
younger than 5 years and those with HIV without 
requiring tuberculosis infection testing, scaling up this 
recommendation to include older children and adolesc-
ents would be a logical irst step to expanding the use 
of preventive therapy, given that the treat-all approach 
would probably lead to more protection and a minimal 
increase in adverse events. For adults, our indings give a 
sense of the anticipated numbers of tuberculosis cases 
and potential severe adverse events associated with each 
approach. These results suggest that as treatment is 
expanded to older age groups, it is crucial for programmes 
to build systems that can identify and manage adverse 
events. Moreover, risk stratiication using infection 
testing and the use of non-isoniazid-containing regimens 
can reduce the number of individuals exposed to toxicity 
from preventive therapy. Use of IGRA might favour 
testing-based risk stratiication, as current IGRAs have 
higher sensitivity than TST.10 Finally, although our 
analysis did not evaluate costs, the framework we present 
could help programmes perform cost assessments to 
inform policies. Infection testing, administration of pre-
ventive therapy, monitoring and managing adverse 
events, and treating incident tuberculosis cases all incur 
costs to health-care systems and patients, and these costs 
vary by context. Knowing the relative numbers of each of 
these outcomes could help programmes compare local 
costs of diferent strategies.
Our modelling exercise complements previous work 
evaluating preventive therapy strategies. Our model 
considered only age and TST positivity as risk factors for 
disease progression; however, the model considered 
multiple preventive therapy regimens and quantiied 
both tuberculosis disease and adverse event outcomes. 
Previous studies that used more detailed sets of risk 
factors to create tools for predicting disease progression 
have either not considered adverse events or have only 
considered hepatitis associated with isoniazid preventive 
therapy.24,25 Additionally, research into biomarkers that 
in the future might provide better predictive value for 
risk of tuberculosis disease progression than existing 
tuberculosis infection tests is ongoing.26
A major limitation of our approach was that we 
considered two binary outcomes but did not attempt 
to quantify their relative importance. In reality, both 
tuberculosis disease and severe adverse events are 
associated with a spectrum of patient experiences, and 
diferent people might view their relative importance 
diferently.27 New methods that jointly analyse competing 
eicacy and safety risks have recently been proposed for 
preventive therapy trials,28 and could in the future be 
adapted for modelling a gradient of outcomes.
Another limitation of the outcomes in our model is 
that they do not capture future consequences of 
tuberculosis disease. Untreated active disease is linked to 
tuberculosis transmission in families and communities, 
impacting people other than the patient. If we had 
modelled these outcomes, the treat-all approach would 
probably be more favourable than the treat-TST-positive-
Figure 3: Difference in risks of incident tuberculosis and severe adverse events associated with a treat-all 
approach versus a treat-TST-only approach, by preventive therapy regimen, age group, and prevalence of 
TST positivity
Error bars represent IQRs. TST=tuberculin skin test.
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only approach given that people who develop tuberculosis 
disease would be at risk of adverse events from 
tuberculosis treatment and could contribute to additional 
cases. We would expect adverse events among the small 
number of adults treated for active disease to be 
outnumbered by adverse events among the much larger 
group receiving preventive therapy, resulting in small 
changes to our adverse event analysis. Diferences in 
incident tuberculosis would be highly dependent on 
assumptions made about reproduction number and the 
timeframe put on the analysis.
Our study was also limited by available data for our 
model parameters. First, age-stratiied data on the natural 
history of tuberculosis progression following infection 
were limited, and we used a study from Australia because 
it had high-quality follow-up data and sought to remove 
the efect of preventive therapy.2 However, disease 
progression risks might not be the same in high-burden 
settings where baseline comorbidities and risks of 
community infection difer. Furthermore, our analysis 
does not incorporate the efect of sex, HIV status, low 
body-mass index, diabetes, or large TST reaction size, all 
of which are associated with increased risk of progression 
to tuberculosis disease.29 Second, we chose to use data on 
eicacy and adverse events from clinical trials because of 
high data quality, meaning that our model is limited to 
drug-susceptible tuberculosis, as results from ongoing 
trials for preventive therapy for drug-resistant 
tuberculosis are not yet known. Moreover, outcomes in 
clinical trials can difer from what is observed in 
programmatic settings, and increased adherence in 
clinical trial populations might lead to both greater 
eicacy and more adverse events than under 
programmatic conditions. Finally, our model 
simplistically assumed complete uptake of preventive 
treatment.
In conclusion, our results suggest that in high-burden 
settings, making all contacts eligible for preventive 
therapy will reduce incident tuberculosis in this 
population. The risk of adverse events can be minimised 
by using regimens that do not contain isoniazid and, 
in adults older than 18 years, focusing treatment on 
individuals with a positive test for infection. Tuberculosis 
programmes in high-burden settings could use the 
results of this study to project risks of tuberculosis and 
severe adverse events, which along with logistical 
considerations, might help programmes decide when to 
incorporate tuberculosis infection testing into contact 
management algorithms. Moreover, future prospective 
studies nested within programmes that evaluate incident 
disease, adverse events, and costs could help validate and 
reine these results, providing a stronger evidence base 
for programmes to make policy decisions based on their 
local epidemiological situation.
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